Responses
Ovarian cancer
2022-RA-1274-ESGO Preliminary data about correlation between CA125 increase and recist progression in patients with relapsed ovarian cancer treated with maintenance PARP inhibitors or bevacizumab after response to platinum based chemotherapy
Compose a Response to This Article
Other responses
No responses have been published for this article.